Yale IR

What a great day at Yale's Advancing Care in Liver Cancer: Surveillance, Team-Based Care, and Emerging Therapies — A Patient and Community Symposium! It was wonderful to bring together patients, families, members of the community, and experts from across our multidisciplinary liver cancer team for a day of informative presentations and engaging discussions. I had the opportunity to speak about integrating liver-directed therapies into multidisciplinary liver cancer care. Throughout the program, there were many thoughtful questions from attendees, leading to valuable discussions about the different aspects of liver cancer care. A particular highlight was hearing from two patients who shared their personal experiences with liver cancer. The multidisciplinary approach is particularly important in liver cancer, where patients may benefit from a number of different treatment options throughout the course of their care. The symposium was also recorded, and we hope to share the presentations with those who were unable to attend. Many thanks to the organizers, speakers, and especially the patients and families who joined us and contributed to such a successful program. #LiverCancer #InterventionalOncology #MultidisciplinaryCare #CancerCare @YaleMed @YaleRadiology @Yale_IR @YaleIMed @YaleDigestive @YaleLiverCancer @YaleCancer @SmilowCancer @MarioStrazzabos @CatherineMezza1 @sundar__raghav

I am pleased to share a recent scientific exchange in the @JVIRmedia regarding our pilot study of single-session transarterial embolization (TAE) with ethiodized oil staining followed by microwave ablation (MWA) for complex central renal cell carcinoma. Jens Borgbjerg and colleagues published a thoughtful Letter to the Editor, and @Ahmed_Farhan97 and I had the opportunity to respond. I have attached our Reply. The original Letter can be found at jvir.org/article/S1051-0443(…. The central question is not whether microwave ablation should replace cryoablation. Rather, it is whether adjunctive transarterial embolization can help overcome some of the historical limitations of heat-based thermal ablation and safely expand its application to carefully selected patients with complex central renal tumors. Our initial study was a small pilot study designed to establish technical feasibility and generate hypotheses, not to demonstrate superiority of one ablation modality over another. The broader question is the role of embolization as an adjunct to thermal ablation, regardless of the ablation modality. Ultimately, this will require larger prospective studies and direct comparative investigation. Thank you to Dr. Borgbjerg and colleagues for initiating an important scientific discussion, and to Ahmed Farhan for his continued work on this project. Original study: jvir.org/article/S1051-0443(… #InterventionalRadiology #InterventionalOncology #RenalCellCarcinoma #TumorAblation #JVIR @YaleMed @YaleRadiology @Yale_IR @YaleCancer @SIRspecialists @SIR_ECS @SIRRFS

Hot off the press! Our new review, “Locoregional therapies for intrahepatic cholangiocarcinoma: a stage-stratified, biology-informed multidisciplinary framework,” is now published in Chinese Clinical Oncology. Jonathan Tefera and I review the evolving role of locoregional therapies in the management of intrahepatic cholangiocarcinoma (iCCA), including future liver remnant augmentation, ablation, TACE, TARE, hepatic arterial infusion chemotherapy, and SBRT. Importantly, we discuss how these therapies can be integrated with surgery and modern systemic therapies across the disease continuum. As treatment options for iCCA continue to expand, multidisciplinary patient selection and appropriate sequencing of locoregional and systemic therapies will become increasingly important. The full article can be found at cco.amegroups.org/article/vi… #InterventionalOncology #InterventionalRadiology #Cholangiocarcinoma #LiverCancer #Oncology #Radiology @jomi9601 @YaleRadiology @Yale_IR @YaleIMed @YaleSurgery @YaleMed @YaleCancer @SmilowCancer @SIRspecialists @SIO_Central @cirsesociety @ECIOcongress @ISMIO_official @curecc @AASLDtweets @EASLnews @AHPBA

Please join us for our upcoming Advancing Care in Liver Cancer: Surveillance, Team-Based Care, and Emerging Therapies — A Patient and Community Symposium on Saturday, October 17 at Yale. This program will bring together patients, families, members of the community, and experts from across our multidisciplinary liver cancer team to discuss surveillance and early detection, liver-directed therapies, transplantation, emerging treatments and clinical trials, and survivorship. I will be speaking about integrating liver-directed therapies into multidisciplinary liver cancer care and will also moderate a discussion focused on collaborating with our patients to improve care. The multidisciplinary approach is particularly important in liver cancer, where patients may benefit from a number of different treatment options throughout the course of their care. I look forward to what should be a very informative and interactive program. Saturday, October 17 | 9:00 AM–2:00 PM The Greenberg Center | 391 Prospect Street, New Haven #LiverCancer #InterventionalOncology #MultidisciplinaryCare #CancerCare #YaleCancerCenter @YaleMed @YaleRadiology @Yale_IR @YaleIMed @YaleDigestive @YaleLiverCancer @YaleSurgery @YaleCancer @SmilowCancer @MarioStrazzabos @sundar__raghav @JakabSimona

I am looking forward to participating in the upcoming @SIO_Central Resident and Medical Student Section (RMSS) Journal Club on liver venous deprivation (LVD). We'll review the evolution of hepatic augmentation strategies, the rationale and technical approach behind combined portal and hepatic vein embolization (PVE/HVE), and the clinical evidence supporting liver venous deprivation, including the DRAGON-1 study. We'll also discuss the design and rationale of the ongoing DRAGON-2 trial, as well as the role of LVD in optimizing the future liver remnant before major hepatic resection. I hope to see you there on August 13! @Yale_IR @YaleRadiology @YaleMed @YaleCancer @SmilowCancer @YaleIMed @YaleSurgery